Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?

Ann Oncol. 2005 Mar;16(3):516-7. doi: 10.1093/annonc/mdi078. Epub 2005 Jan 10.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Doxorubicin / administration & dosage
  • Doxorubicin / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Predictive Value of Tests
  • Prognosis
  • Receptor, ErbB-2 / biosynthesis*
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Biomarkers, Tumor
  • Doxorubicin
  • Receptor, ErbB-2